Antigen News and Research

RSS

Cancer screening methods are not perfect: Experts

In a recent New York Times article, the American Cancer Society (ACS) ignited a major controversy over the benefits of cancer screening, specifically with regards to their breast and prostate cancer guidelines. In the article, Dr. Otis Brawley, chief medical officer of the ACS, responded to a study in the current issue of the Journal of the American Medical Association.

11 Nov 2009

Prostate size growth not necessarily a predictor of development of cancer

New Mayo Clinic research studied the association between prostate-specific antigen (PSA) levels and prostate size and found that routine annual evaluation of prostate growth is not necessarily a predictor for the development of prostate cancer. However the study suggests that if a man's PSA level is rising quickly, a prostate biopsy is reasonable to determine if he has prostate cancer.

11 Nov 2009

New HPV vaccine eliminates chronic infection and reduces precancerous genital lesions in women

A new vaccine designed to stimulate an immune response against a cancer-causing human papillomavirus (HPV-16) can eliminate chronic infection by the virus and may cause regression of precancerous genital lesions in women who receive the vaccine.

11 Nov 2009

Aduro BioTech raises funds through its Series A-1 financing

Aduro BioTech, a privately held biotechnology company focused on the development of therapeutic and prophylactic vaccines based on proprietary recombinant strains of the bacterium Listeria monocytogenes, today announced completion of its Series A-1 financing.

10 Nov 2009

Tokai Pharmaceuticals commences TOK-001 Phase 1/2 clinical trial for treatment of castration resistant prostate cancer

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the treatment of patients with castration resistant prostate cancer (CRPC). TOK-001 is the only compound in development that combines three distinct mechanisms of action for the treatment of CRPC.

10 Nov 2009

ImmunoGen to present IMGN901 clinical data at AACR-NCI-EORTC International Conference

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that several ImmunoGen poster presentations will be made at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held in Boston, MA, on November 15-19, 2009.

10 Nov 2009

OriGene Technologies' over-expression lysates adopted for Human Protein Atlas project

OriGene Technologies, Inc. today announced Royal Institute of Technology in Sweden has adopted its VERIFY Tagged Antigen(TM) (Over-expression Lysates) in the Human Protein Atlas program. This program is funded by the Knut and Alice Wallenberg Foundation and is set up to explore the human proteome systematically using Antibody-Based Proteomics.

10 Nov 2009

Researchers discover cells that protect the respiratory tract from developing an allergic response

According to the great paradigms of immunology, asthma, an allergic disease of the respiratory system, should always develop upon exposure to airborne antigens that are constantly being inhaled. However, the fact that 94 % of the Western population does not develop the disease suggests that as yet undefined mechanisms protect the respiratory tract from developing an allergic response. A team of researchers at University of Liege (Belgium), GIGA Research Center, led by Professor Fabrice Bureau, has shown that asthma is inhibited by regulatory macrophages, a cell population never previously described.

10 Nov 2009

Chicago Prostate Cancer Center offers free prostate cancer guide

Prostate cancer is the second most common cancer in American men. One in six men will be diagnosed during his lifetime, according to the American Cancer Society.

9 Nov 2009

Cellular mechanisms that may impact immune functions in the elderly discovered

Investigators discover cellular mechanisms that may impact the decline of both innate and adaptive immune functions that increase the susceptibility to various infectious agents, cancer and diseases in the elderly say experts at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Miami Beach, Fla.

9 Nov 2009

Elevated PSA levels in men are not necessarily a predictor of the need for a prostate biopsy: Study

Researchers at Wake Forest University School of Medicine and the University of Wisconsin-Madison have discovered that some elevated prostate-specific antigen (PSA) levels in men may be caused by a hormone normally occurring in the body, and are not necessarily a predictor of the need for a prostate biopsy.

7 Nov 2009

Changes in PSA over time aid prostate cancer detection

The November issue of European Urology, the official journal of the European Association of Urology, features an article focussing on prostate specific antigen (PSA) velocity and early cancer detection. It has been suggested that changes in PSA over time aid prostate cancer detection.

6 Nov 2009

Combination therapy before prostate removal may prevent recurrence of cancer

Researchers in the Oregon Health & Science University Knight Cancer Institute and the Portland Veterans Affairs Medical Center have found a combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the potential to reduce cancer recurrence and improve patient survival.

4 Nov 2009

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

EUSA Pharma announced that PROSTASCINT® (capromab pendetide) fusion imaging was shown to effectively guide prostate cancer therapy targeting and dosing and is a significant predictor of disease free survival, according to data presented on Tuesday, November 3, 2009 at the 51st American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting in Chicago, Illinois.

4 Nov 2009

Celldex announces third quarter and nine-month period results; acquires a net loss of $7.2 million

Celldex Therapeutics, Inc. today reported financial results for the third quarter and nine-month period ended September 30, 2009. Celldex reported a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009 compared to a net loss of $7.7 million, or $0.49 per share, for the third quarter of 2008.

4 Nov 2009

Patients who have an undetectable level of PSA after therapy have good chance of being cured

Fox Chase Cancer Center researchers report that radiation therapy alone can reduce prostate specific antigen (PSA) levels below detectable amounts in prostate cancer patients. Patients who have an undetectable level of PSA after therapy have less chance of biochemical failure than other patients and a good chance of being cured.

4 Nov 2009

Hospitalization and death of H1N1 patients can occur at all ages, says study

In contrast with some common perceptions regarding 2009 influenza A(H1N1) infections, an examination of cases in California indicates that hospitalization and death can occur at all ages, and about 30 percent of hospitalized cases have been severe enough to require treatment in an intensive care unit, according to a study in the November 4 issue of JAMA.

4 Nov 2009

AUA clarifes recommendations on prostate cancer testing with PSA test and DRE

The American Urological Association (AUA) is aware of recent news reports disparaging prostate cancer testing. We are concerned that these reports are causing significant confusion for patients and we wish to clarify our recommendations on prostate cancer testing with the prostate-specific antigen (PSA) test and digital rectal exam (DRE). The AUA strongly supports early prostate cancer detection and feels it is in a man's best interest to consider being tested for prostate cancer.

4 Nov 2009

Blood vessels good indicators of prostate cancer behavior

A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed?

4 Nov 2009

Mechanical force switches T cell from disease-scanning to disease-fighting mode

The immune system's T cells have the unique responsibilities of being both jury and executioner. They examine other cells for signs of disease, including cancers or infections, and, if such evidence is found, rid them from the body. Precisely how T cells shift so swiftly from one role to another, however, has been a mystery.

3 Nov 2009

Antigen News and Research

Cancer screening methods are not perfect: Experts

Prostate size growth not necessarily a predictor of development of cancer

New HPV vaccine eliminates chronic infection and reduces precancerous genital lesions in women

Aduro BioTech raises funds through its Series A-1 financing

Tokai Pharmaceuticals commences TOK-001 Phase 1/2 clinical trial for treatment of castration resistant prostate cancer

ImmunoGen to present IMGN901 clinical data at AACR-NCI-EORTC International Conference

OriGene Technologies' over-expression lysates adopted for Human Protein Atlas project

Researchers discover cells that protect the respiratory tract from developing an allergic response

Chicago Prostate Cancer Center offers free prostate cancer guide

Cellular mechanisms that may impact immune functions in the elderly discovered

Elevated PSA levels in men are not necessarily a predictor of the need for a prostate biopsy: Study

Changes in PSA over time aid prostate cancer detection

Combination therapy before prostate removal may prevent recurrence of cancer

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

Celldex announces third quarter and nine-month period results; acquires a net loss of $7.2 million

Patients who have an undetectable level of PSA after therapy have good chance of being cured

Hospitalization and death of H1N1 patients can occur at all ages, says study

AUA clarifes recommendations on prostate cancer testing with PSA test and DRE

Blood vessels good indicators of prostate cancer behavior

Mechanical force switches T cell from disease-scanning to disease-fighting mode

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest Life Science News